Evidence map›Paper›PMID 33910875›Full record

Observational studyIn vivo (Athens, Greece)

Lung Cancer, Covid-19 Infections and Chemotherapy.

Bogdan Haineala, Anca Zgura, Dumitru Cristinel Badiu, Laura Iliescu, Rodica Maricela Anghel, Xenia Elena Bacinschi

Open access · diamondAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Bogdan HainealaDepartment of Urology, "Fundeni" Clinical Institute, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
Anca ZguraDepartment of Oncology-Radiotherapy, "Prof. Dr. Alexandru Trestioreanu" Institute of Oncology, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania; medicanca@gmail.com.
Dumitru Cristinel BadiuGeneral Surgery Department, "Prof. Dr. Bagdasar Arseni" Clinical Emergency Hospital, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
Laura IliescuII Department of Internal Medicine, "Fundeni" Clinical Institute, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
Rodica Maricela AnghelDepartment of Oncology-Radiotherapy, "Prof. Dr. Alexandru Trestioreanu" Institute of Oncology, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
Xenia Elena BacinschiDepartment of Oncology-Radiotherapy, "Prof. Dr. Alexandru Trestioreanu" Institute of Oncology, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
Carol Davila University of Medicine and Pharmacy · RO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimThe Covid-19 epidemic has severely strained health care systems across the globe. The impacts are multiple especially for patients cared for cancer. The Covid-19 epidemic has several impacts on the management of lung cancer patients. The aim of this work was to summarize the available epidemiological data on patients diagnosed with lung cancer infected with Covid-19 and describe the different strategies to improve the management of these patients by summarizing the recommendations in this area. PATIENTS AND

methodsThe Teravolt cohort is an observational multicenter registry, including patients with non-small cell cancer, small cell cancer or mesothelioma but also epithelial tumors and a diagnosis of Covid-19. The Theravolt registry indicates an unexpectedly high mortality rate in patients with thoracic malignancies with COVID-19.

resultsBetween March 26 and April 12, 2020, 200 patients treated in 8 countries were included. They had a performance status (PS) of 0-1 in 72% of cases, were smokers or ex-smokers in 81% of cases, had non-small cell cancer (76% of cases), were under treatment in 74% of cases, and the majority were first-line cases (57%). The hospitalization rate was 76% and the mortality rate 33%; only 10% of patients with criteria for intensive care hospitalization were admitted to the intensive care.

conclusionData presented in this registry suggest a high mortality in patients with thoracic cancer and Covid-19. Therofere, the importance to create a safe healthcare system during Covid-19 pandemic is underlined along with the need for essential effective clinical service delivery to patients with lung cancer.

Indexed as

COVID-19Lung NeoplasmsHospitalizationHumansPandemicsSARS-CoV-2chemotherapyCovid-19 infectionimmunotherapyLung cancerrecommendations

Identifiers

PMID33910875
PMCPMC8193347
OpenAlexW3157813227

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.